Drugs Containing Excipient (Inactive Ingredient) POLYOXYL 15 HYDROXYSTEARATE

Branded drugs containing POLYOXYL 15 HYDROXYSTEARATE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sun Pharmaceutical Industries Inc	XELPROS	latanoprost	47335-317	POLYOXYL 15 HYDROXYSTEARATE

Generic drugs containing POLYOXYL 15 HYDROXYSTEARATE excipient

Company	Ingredient	NDC	Excipient
Sun Pharmaceutical Industries Inc	latanoprost	47335-317	POLYOXYL 15 HYDROXYSTEARATE

Polyoxyl 15 Hydroxystearate Market Dynamics, Patent Position, and Financial Trajectory

Last updated: August 7, 2026

Polyoxyl 15 hydroxystearate is a specialty pharmaceutical excipient used primarily as a nonionic solubilizer, emulsifier, and wetting agent. The material is known commercially as Kolliphor HS 15 and was previously associated with the Solutol HS 15 trade name. BASF is the principal globally visible supplier. Product-specific revenue, market share, and profitability are not publicly disclosed because the material is reported within broader excipients or Care Chemicals segments rather than as a separate financial line item.

Demand is tied to injectable, oral, and lipid-based drug delivery systems, particularly for poorly water-soluble active pharmaceutical ingredients. The market has relatively low direct substitution risk in technically validated formulations but remains exposed to supplier qualification costs, raw-material inflation, regulatory documentation requirements, and competition from polysorbates, poloxamers, polyethylene glycol derivatives, cyclodextrins, and lipid excipients.

What is Polyoxyl 15 Hydroxystearate and how is it used?

Polyoxyl 15 hydroxystearate is an ethoxylated derivative of hydroxystearic acid. It is a nonionic surfactant and amphiphilic excipient composed of a hydrophobic hydroxystearate component linked to polyethylene glycol chains. Because it is a defined chemical mixture rather than a single small molecule, specifications typically address composition, hydroxyl value, acid value, water content, residual solvents, ethylene oxide-related impurities, and performance characteristics.

Key identifiers include:

Attribute	Data
Compendial name	Polyoxyl 15 hydroxystearate
European compendial name	Macrogol 15 hydroxystearate
Common trade name	Kolliphor HS 15
Historical trade name	Solutol HS 15
CAS number commonly associated with material	70142-34-6
Excipient class	Nonionic surfactant, solubilizer, emulsifier
Typical formulation role	Solubilization, wetting, dispersion, emulsion stabilization
Primary dosage forms	Injectable, oral liquid, capsule, suspension, and lipid-based systems
Regulatory category	Pharmaceutical excipient, not an active pharmaceutical ingredient

The material is attractive for formulations requiring improved aqueous dispersion of lipophilic drug substances. It can form micellar or mixed colloidal systems and is generally selected during preformulation when the active ingredient has low aqueous solubility.

BASF identifies Kolliphor HS 15 as a solubilizer for parenteral and oral dosage forms and markets it through its pharmaceutical excipients portfolio.[1]

What pharmaceutical formulations use Polyoxyl 15 Hydroxystearate?

Polyoxyl 15 hydroxystearate is used where a formulation requires a balance between solubilization capacity, manufacturability, and tolerability. Its use is most relevant in the following systems:

Parenteral formulations

The excipient is used in injectable development for poorly soluble drug substances. Its technical value is highest when it can reduce dependence on organic solvents, improve solution clarity, or support a lower injection volume.

Parenteral use faces the highest regulatory burden. Sponsors must evaluate hemolysis, irritation, complement activation, hypersensitivity, extractables and leachables, particulate formation, and compatibility with containers and infusion equipment. A supplier change can require substantial comparability work even when the chemical name remains unchanged.

Oral and liquid formulations

Polyoxyl 15 hydroxystearate can improve wetting and dispersion in oral liquids, suspensions, and lipid-based delivery systems. It may also be used in self-emulsifying or micellar formulations for poorly soluble compounds.

Oral applications generally face lower safety and administration risks than intravenous products, but taste, gastrointestinal tolerability, physical stability, and interaction with capsule shells or packaging remain relevant.

Biopharmaceutical and specialty delivery systems

The excipient can appear in development programs involving complex drug-delivery systems, although it is not itself a biologic excipient in the same strategic category as polysorbate 20, polysorbate 80, or poloxamer 188. For biologics, oxidation, peroxide content, aggregation, and protein-surfactant interactions are critical. Use in biologics is therefore formulation-specific and cannot be inferred from broad excipient approval status.

How large is the Polyoxyl 15 Hydroxystearate market?

No reliable public market estimate isolates Polyoxyl 15 hydroxystearate from the wider pharmaceutical excipients, specialty surfactants, or solubilizer markets. Commercial market reports generally aggregate multiple excipient classes and do not provide audited product-level revenue.

The financial market can be assessed through three layers:

Market layer	Public visibility	Financial relevance
Polyoxyl 15 hydroxystearate SKU sales	Very limited	Not separately reported
Pharmaceutical solubilizers and surfactants	Partial	Included in specialty excipient estimates
BASF pharmaceutical excipients and Care Chemicals	Reported at segment level	Provides supplier-level direction, not product revenue

BASF reports pharmaceutical excipients within broader business structures and does not disclose revenue, gross margin, or operating profit for Kolliphor HS 15 separately.[2] Any precise global revenue figure for Polyoxyl 15 hydroxystearate should therefore be treated as an estimate rather than audited market data.

The commercial opportunity is likely concentrated rather than volume-driven. High-purity pharmaceutical grades command a premium over industrial surfactants because buyers pay for documentation, batch consistency, regulatory support, supply continuity, and change-control management. A modest volume market can therefore support attractive unit economics when the product is qualified in approved injectable or specialty formulations.

What is the financial trajectory for Polyoxyl 15 Hydroxystearate?

The likely financial trajectory is steady growth with periodic volatility rather than a rapid volume expansion. Four factors shape the outlook.

First, formulation demand is increasing for solubilizers as drug pipelines contain a high proportion of poorly water-soluble compounds. This supports continued use of nonionic surfactants in discovery, clinical development, and commercial products.

Second, sales are affected by the development cycle. Excipient demand can rise during formulation screening but fall when a program is discontinued, reformulated, or shifted to a different delivery platform. Commercial demand is more stable but depends on a small number of qualified products.

Third, the product is exposed to raw-material and energy costs. Manufacturing requires fatty-acid derivatives, ethylene oxide-derived inputs, process utilities, quality testing, and specialized packaging. Energy and chemical input inflation can pressure margins when contracts do not include pass-through provisions.

Fourth, supplier qualification creates retention. Once an excipient is validated in a commercial product, the drug manufacturer often avoids switching suppliers unless price, capacity, quality, or regulatory risk becomes material. This provides recurring revenue characteristics that are stronger than those of unqualified development-grade material.

Base-case commercial outlook

The base case is low-to-mid single-digit annual growth in pharmaceutical demand, driven by poorly soluble small molecules, injectable formulation activity, and greater use of enabling excipients. This is an analytical market view, not a reported company forecast.

Upside case

Growth could exceed the broader excipient market if:

• More injectable products replace solvent-heavy formulations.
• New lipid-based delivery platforms adopt the material.
• A supplier obtains additional regulatory acceptances or expands regional manufacturing.
• Customers qualify the excipient in higher-volume commercial products.

Downside case

Demand could weaken if:

• Formulators shift to poloxamers, polysorbates, cyclodextrins, or lipid excipients.
• A safety, impurity, or supply-continuity concern affects a major grade.
• Sponsors reduce development spending on poorly soluble compounds.
• Customers demand dual sourcing and place greater volume with lower-cost regional suppliers.

Who manufactures Polyoxyl 15 Hydroxystearate?

BASF is the most visible international supplier under the Kolliphor HS 15 brand. Its pharmaceutical excipient business provides regulatory documentation, technical support, and global distribution for drug-product manufacturers.[1]

The competitive environment includes:

1. Branded multinational excipient suppliers with strong regulatory and technical support.
2. Regional manufacturers offering lower-cost material or alternative grades.
3. Contract manufacturers capable of producing custom surfactant systems.
4. Substitute excipient suppliers competing at the formulation level rather than with identical chemistry.

The key competitive advantage is not only manufacturing cost. It is the ability to provide consistent critical quality attributes, pharmacopeial support, impurity control, reliable supply, and documentation suitable for FDA, EMA, and other health-authority submissions.

What patents protect Polyoxyl 15 Hydroxystearate?

The base excipient has limited practical patent exclusivity because polyoxylated fatty-acid derivatives have been used in pharmaceutical and industrial formulations for decades. Composition-of-matter patent protection for the generic excipient itself is not the principal barrier to competition.

The relevant intellectual-property layers are:

IP layer	Relevance
Base composition	Likely mature and generally not a meaningful exclusivity barrier
Manufacturing process	May protect purity, molecular-weight distribution, or impurity control
Supplier grade	Trade secrets, specifications, know-how, and quality systems
Drug formulation	Can protect a particular active ingredient and excipient combination
Method of use	May cover treatment or administration using a formulation containing the excipient
Device or packaging	May protect delivery systems, containers, or infusion configurations

Product-specific formulation patents may remain active even though the excipient is old. Those patents belong to the drug-product sponsor and generally cover the active ingredient, dosage form, concentration, particle size, delivery system, or therapeutic use. They do not create exclusive ownership of Polyoxyl 15 hydroxystearate as a commodity excipient.

What is the Orange Book status of Polyoxyl 15 Hydroxystearate?

Polyoxyl 15 hydroxystearate is not an active pharmaceutical ingredient and does not have an independent Orange Book listing. The FDA Orange Book lists approved drug products and associated patents or exclusivity, not excipients as standalone products.[3]

The excipient may be present in an approved drug whose formulation patents are listed in the Orange Book. In that situation, the patent risk attaches to the drug product and its claims, not automatically to the excipient supplier.

When does Polyoxyl 15 Hydroxystearate lose exclusivity?

The excipient itself does not have a conventional regulatory exclusivity period comparable to a new chemical entity, biologic, orphan drug, or pediatric product. There is no standalone five-year, seven-year, or twelve-year FDA exclusivity period for Polyoxyl 15 hydroxystearate.

Commercial exclusivity is instead created by:

• Customer qualification.
• Proprietary grade specifications.
• Manufacturing know-how.
• Regulatory files and supplier history.
• Long-term supply agreements.
• Drug-product patents using the excipient.
• Switching costs in approved formulations.

This distinction is important. A competing manufacturer may be legally able to produce the same chemical while still facing commercial barriers to qualification and scale-up.

Which companies are challenging the incumbent supplier?

Publicly documented Paragraph IV challenges directed specifically at Polyoxyl 15 hydroxystearate are not a material feature of the market. Paragraph IV litigation applies to patents listed for approved drug products, not to an excipient sold as a standalone pharmaceutical ingredient.

Competitive pressure is more likely to arise through:

• Alternative suppliers seeking drug-master-file acceptance.
• Regional manufacturers offering equivalent grades.
• Formulators replacing the excipient with poloxamers, polysorbates, PEG derivatives, or cyclodextrins.
• Dual-sourcing initiatives by pharmaceutical companies.
• Internal reformulation to reduce cost or improve safety margins.

What regulatory requirements affect market access?

The material must meet applicable pharmacopeial, quality, and manufacturing requirements for its intended use. Buyers typically review:

• USP-NF or Ph. Eur. compliance.
• Certificate of analysis and lot release data.
• Residual ethylene oxide and related impurities.
• Peroxide and aldehyde levels.
• Microbial and endotoxin controls where applicable.
• Elemental impurities.
• Stability and retest data.
• Change-control procedures.
• Manufacturing-site history.
• Drug Master File or equivalent regulatory support.

The FDA Inactive Ingredient Database is a key reference for determining whether an excipient has precedent in approved drug products and by route of administration.[4] IID presence does not guarantee approval for every concentration, route, or formulation. Sponsors must still justify the level used and demonstrate product-specific safety and performance.

What generic entry risks exist for drugs using Polyoxyl 15 Hydroxystearate?

Generic entry risk depends primarily on the approved drug’s active-ingredient patents, formulation claims, regulatory pathway, and substitutability. The excipient creates secondary technical barriers rather than primary exclusivity.

A generic developer may need to address:

• Equivalent solubilization and drug release.
• Particle-size distribution.
• Injection compatibility.
• Stability and degradation products.
• Bioequivalence for complex dosage forms.
• Device and container interaction.
• Analytical similarity where the formulation is colloidal or lipid-based.

For simple oral products, substitution may be manageable. For injectable or complex formulations, the excipient system can increase development cost and regulatory risk, particularly where the reference product depends on a specific micellar or emulsion structure.

What licensing deals and settlement agreements affect the market?

No major public licensing transaction or patent settlement is specifically associated with Polyoxyl 15 hydroxystearate as an excipient. Licensing arrangements are more commonly tied to drug formulations, delivery platforms, or manufacturing technologies that may use the material.

Likewise, Paragraph IV settlements generally resolve patents covering the active drug or drug product. They do not normally resolve ownership of the excipient itself.

How strong is the patent estate for Polyoxyl 15 Hydroxystearate?

The direct patent estate is weak as a standalone chemical asset but can be commercially strong at the formulation and supplier level.

Asset category	Patent strength	Commercial effect
Base excipient chemistry	Low	Open technical competition
Purity and production process	Moderate	Can protect quality differentiation
Branded pharmaceutical grade	Limited patent value	Stronger through qualification and documentation
Drug-specific formulation	Potentially high	Can delay generic entry
Delivery platform using the excipient	Variable to high	Depends on claim scope and remaining term
Supply agreement	Not patent protection	Can secure volume and customer retention

The most defensible business position is therefore based on regulatory execution, manufacturing consistency, supply reliability, and embedded customer relationships rather than on broad composition patents.

What geographic markets matter most?

North America and Europe remain the highest-value regions because of stringent regulatory requirements and concentration of innovative pharmaceutical manufacturing. Asia-Pacific is important for both drug-product growth and excipient production capacity.

Geographic competition is shaped by:

• Local pharmacopeial requirements.
• Import registration.
• Drug Master File acceptance.
• Regional manufacturing qualification.
• Supply-chain resilience.
• Tariffs and logistics.
• Customer preference for dual sourcing.

A supplier with one global production site may face greater customer scrutiny than a supplier with qualified regional capacity. The commercial value of redundancy increased after pandemic-related supply disruptions and broader pharmaceutical supply-chain reviews.

Key Takeaways

• Polyoxyl 15 hydroxystearate is a mature nonionic pharmaceutical surfactant used mainly for solubilization, wetting, and emulsion stabilization.
• Kolliphor HS 15 is the most visible commercial brand, with BASF as the principal global supplier.
• Product-specific revenue and market share are not publicly reported.
• Financial growth is linked to poorly soluble drug pipelines, injectable formulations, and lipid-based delivery systems.
• The excipient has little standalone patent exclusivity. Its commercial defensibility comes from qualification, quality systems, regulatory support, and supply reliability.
• It has no independent Orange Book listing and no standalone FDA exclusivity period.
• Paragraph IV litigation and settlements generally concern drug products that use the excipient, not the excipient itself.
• Generic entry risk is highest for complex injectable and colloidal formulations where matching performance is technically difficult.
• The strongest long-term risks are substitution by other solubilizers, manufacturing-cost inflation, regional competition, and a quality or supply event.
• The financial trajectory is best characterized as stable specialty-excipient growth with limited transparency at the SKU level.

FAQs

Is Polyoxyl 15 hydroxystearate the same as Kolliphor HS 15?

Kolliphor HS 15 is BASF’s commercial brand for a pharmaceutical grade of Polyoxyl 15 hydroxystearate. The trade name identifies a supplier grade, while Polyoxyl 15 hydroxystearate is the generic excipient name.

Is Polyoxyl 15 hydroxystearate used in injectable drugs?

Yes. It is used in development and commercial formulation work for poorly soluble drug substances, including parenteral systems. Each injectable use requires product-specific safety, stability, and compatibility assessment.

Does Polyoxyl 15 hydroxystearate have a drug-master-file strategy?

Pharmaceutical excipient manufacturers commonly provide regulatory packages, technical files, and, where applicable, Drug Master File support. The exact filing status and level of access are supplier-specific and are not equivalent to patent exclusivity.

Can a pharmaceutical company switch suppliers of Polyoxyl 15 hydroxystearate?

Yes, but the change may require qualification, comparability testing, stability work, regulatory notification, or approval depending on the product, route, jurisdiction, and extent of material differences.

What are the main alternatives to Polyoxyl 15 hydroxystearate?

The main formulation alternatives include polysorbates, poloxamers, polyethylene glycol derivatives, cyclodextrins, phospholipids, medium-chain triglycerides, and other lipid or surfactant systems. Selection depends on route, solubilization capacity, toxicity, stability, and regulatory precedent.

References

1. BASF SE. (n.d.). Kolliphor HS 15: Pharmaceutical excipient technical information. BASF Pharma Solutions.
2. BASF SE. (2024). BASF report 2023. Ludwigshafen, Germany: BASF SE.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. Silver Spring, MD: FDA.
4. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. Silver Spring, MD: FDA.
5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. Rockville, MD: USP.
6. European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia. Strasbourg, France: EDQM.